Literature DB >> 26537583

MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells.

Sangmin Kim1, Jeongmin Lee2, Myeongjin Jeon2,3, Jeong Eon Lee2,3, Seok Jin Nam4.   

Abstract

Interleukin-8 (IL-8) serves as a prognostic marker for breast cancer, and its expression level correlates with metastatic breast cancer and poor prognosis. Here, we investigated the levels of IL-8 expression in a variety of breast cancer cells and the regulatory mechanism of IL-8 in triple-negative breast cancer (TNBC) cells. Our results showed that IL-8 expression correlated positively with overall survival in basal-type breast cancer patients. The levels of IL-8 mRNA expression and protein secretion were significantly increased in TNBC cells compared with non-TNBC cells. In addition, the invasiveness of the TNBC cells was dramatically increased by IL-8 treatment and then augmented invasion-related proteins such as matrix metalloproteinase (MMP)-2 or MMP-9. We observed that elevated IL-8 mRNA expression and protein secretion were suppressed by a specific MEK1/2 inhibitor, UO126. In contrast, the overexpression of constitutively active MEK significantly increased the level of IL-8 mRNA expression in BT474 non-TNBC cells. Finally, we investigated the effect of UO126 on the tumorigenecity of TNBC cells. Our results showed that anchorage-independent growth, cell invasion, and cell migration were also decreased by UO126 in TNBC cells. As such, we demonstrated that IL-8 expression is regulated through MEK/ERK-dependent pathways in TNBC cells. A diversity of MEK blockers, including UO126, may be promising for treating TNBC patients.

Entities:  

Keywords:  Cell invasion; IL-8; MEK; Poor prognosis; Triple-negative breast cancer

Mesh:

Substances:

Year:  2015        PMID: 26537583     DOI: 10.1007/s13277-015-4345-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Targeting the leptin receptor: a potential new mode of treatment for breast cancer.

Authors:  Laszlo Otvos; Eva Surmacz
Journal:  Expert Rev Anticancer Ther       Date:  2011-08       Impact factor: 4.512

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  ERβ and PEA3 co-activate IL-8 expression and promote the invasion of breast cancer cells.

Authors:  Ying Chen; Li Chen; Ji-Yu Li; Naofumi Mukaida; Qiaoqiao Wang; Chen Yang; Wen-Jin Yin; Xiao-Hua Zeng; Wei Jin; Zhi-ming Shao
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

4.  Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.

Authors:  K Inoue; J W Slaton; B Y Eve; S J Kim; P Perrotte; M D Balbay; S Yano; M Bar-Eli; R Radinsky; C A Pettaway; C P Dinney
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

5.  Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin-8 promoter. The role of Oct-1 as a transcriptional repressor.

Authors:  G D Wu; E J Lai; N Huang; X Wen
Journal:  J Biol Chem       Date:  1997-01-24       Impact factor: 5.157

Review 6.  New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression.

Authors:  Brigitte Bauvois
Journal:  Biochim Biophys Acta       Date:  2011-10-12

7.  IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells.

Authors:  Yusuke Itoh; Takashi Joh; Satoshi Tanida; Makoto Sasaki; Hiromi Kataoka; Keisuke Itoh; Tadayuki Oshima; Naotaka Ogasawara; Shouzo Togawa; Tsuneya Wada; Hidetsugu Kubota; Yoshinori Mori; Hirotaka Ohara; Tomoyuki Nomura; Shigeki Higashiyama; Makoto Itoh
Journal:  Cytokine       Date:  2005-03-21       Impact factor: 3.861

Review 8.  The interleukin-8 pathway in cancer.

Authors:  David J J Waugh; Catherine Wilson
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

9.  Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK).

Authors:  L F Lee; G Li; D J Templeton; J P Ting
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

10.  Serum IL-8 and IL-12 levels in breast cancer.

Authors:  Duygu Derin; Hilal Oguz Soydinc; Nese Guney; Faruk Tas; Hakan Camlica; Derya Duranyildiz; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

View more
  11 in total

1.  Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways.

Authors:  Feng Qi; Wen-Xing Qin; Yuan-Sheng Zang
Journal:  Oncol Lett       Date:  2019-01-03       Impact factor: 2.967

2.  Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.

Authors:  Charli Dominguez; Kristen K McCampbell; Justin M David; Claudia Palena
Journal:  JCI Insight       Date:  2017-11-02

3.  Fibronectin Functions as a Selective Agonist for Distinct Toll-like Receptors in Triple-Negative Breast Cancer.

Authors:  Anthony Ambesi; Pranav Maddali; Paula J McKeown-Longo
Journal:  Cells       Date:  2022-06-30       Impact factor: 7.666

4.  Acetylshikonin suppresses invasion of Porphyromonas gingivalis‑infected YD10B oral cancer cells by modulating the interleukin-8/matrix metalloproteinase axis.

Authors:  Bong-Hae Cho; Yun-Hoa Jung; Da Jeong Kim; Bok Hee Woo; Ji Eun Jung; Ji Hye Lee; Young Whan Choi; Hae Ryoun Park
Journal:  Mol Med Rep       Date:  2017-11-24       Impact factor: 2.952

5.  Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer.

Authors:  Rosa Mistica C Ignacio; Carla R Gibbs; Soohyun Kim; Eun-Sook Lee; Samuel E Adunyah; Deok-Soo Son
Journal:  Oncotarget       Date:  2019-01-11

6.  Celastrol attenuates the inflammatory response by inhibiting IL‑1β expression in triple‑negative breast cancer cells.

Authors:  Daeun You; Yisun Jeong; Sun Young Yoon; Sung A Kim; Seok Won Kim; Seok Jin Nam; Jeong Eon Lee; Sangmin Kim
Journal:  Oncol Rep       Date:  2021-04-13       Impact factor: 3.906

7.  Entelon® (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells.

Authors:  Daeun You; Yisun Jeong; Sun Young Yoon; Sung A Kim; Eunji Lo; Seok Won Kim; Jeong Eon Lee; Seok Jin Nam; Sangmin Kim
Journal:  Molecules       Date:  2021-06-15       Impact factor: 4.411

8.  HIV-1 matrix protein p17 and its variants promote human triple negative breast cancer cell aggressiveness.

Authors:  Francesca Caccuri; Francesca Giordano; Ines Barone; Pietro Mazzuca; Cinzia Giagulli; Sebastiano Andò; Arnaldo Caruso; Stefania Marsico
Journal:  Infect Agent Cancer       Date:  2017-09-25       Impact factor: 2.965

9.  Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways.

Authors:  Pablo Garrido; Aliaa Shalaby; Elaine M Walsh; Nessa Keane; Mark Webber; Maccon M Keane; Francis J Sullivan; Michael J Kerin; Grace Callagy; Aideen E Ryan; Sharon A Glynn
Journal:  Oncotarget       Date:  2017-07-26

Review 10.  Recent advances in nanotheranostics for triple negative breast cancer treatment.

Authors:  Vikram Thakur; Rajaletchumy Veloo Kutty
Journal:  J Exp Clin Cancer Res       Date:  2019-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.